Aurinia Pharmaceuticals (AUPH) stock is in focus after the company reiterated its 2026 revenue guidance and reported second quarter earnings, along with an update on its ongoing share repurchase program.
See our latest analysis for Aurinia Pharmaceuticals.
At a share price of $15.45, Aurinia Pharmaceuticals has seen modest short term share price gains over the past week. Its 1 year total shareholder return of 28.64% and 3 year total shareholder return of 58.62% point to momentum that has built over a longer horizon.
If Aurinia’s guidance and buyback have you thinking about other potential ideas in healthcare, this could be a helpful moment to scan 43 healthcare AI stocks.
Aurinia Pharmaceuticals is putting up solid revenue and earnings figures, backed by a sizeable buyback, while the stock has already delivered strong multi year returns. The question now is how that business profile lines up with today’s valuation.
Most Popular Narrative: 26.4% Undervalued
Aurinia Pharmaceuticals last closed at $15.45, while the most followed narrative points to a fair value of $21.00. That gap is what puts this story back in focus.
For investors who value regime resilience and signal clarity, Aurinia offers exposure to autoimmune therapeutics without the chaos of multi‑asset pipelines. The next twelve months will test whether simplicity can continue to outperform the noise of biotech volatility, but for now, the signal remains strong.
Want to see what sits behind that fair value for Aurinia Pharmaceuticals? The narrative leans hard on revenue traction, thick margins and a valuation multiple that assumes real staying power in earnings quality. The exact mix of those inputs might surprise you.
Result: Fair Value of $21.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Aurinia Pharmaceuticals still faces risks, including potential competition in lupus nephritis and execution setbacks in long dated programs like aritinercept that could challenge this narrative.
Find out about the key risks to this Aurinia Pharmaceuticals narrative.
Next Steps
With both risks and rewards in play around Aurinia Pharmaceuticals, this is a good time to move fast, review the data and form your own view. To see how the full risk and reward picture stacks up, take a closer look at the 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond Aurinia Pharmaceuticals?
Do not stop with Aurinia Pharmaceuticals. Use this momentum to widen your watchlist with other focused ideas that could sharpen your overall portfolio.
- Target potential mispricings by scanning for quality companies that still trade at a discount through the 48 high quality undervalued stocks.
- Strengthen your income stream by checking out companies that pay substantial yields in the 10 dividend fortresses.
- Prioritise resilience by reviewing businesses that show financial durability using the 85 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com